This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Headquartered in Woonsocket, RI, CVS Health Corporation (formerly known as CVS Caremark Corporation) is a pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care. On Sep 3, 2014, CVS Caremark Corporation announced a change of its corporate name to CVS Health to reflect its broader health care commitment. In Nov 2018, CVS Health completed the $70-billion consolidation of insurance-giant Aetna. With the acquisition, the segments of CVS Health have been realigned.
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RSPH
Here's Why You Should Retain CVS Health (CVS) Stock for Now
by Zacks Equity Research
Investors are optimistic about CVS Health's (CVS) strength in Health Care Benefits business arm and stable solvency position.
Here is What to Know Beyond Why CVS Health Corporation (CVS) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to CVS Health (CVS). This makes it worthwhile to examine what the stock has in store.
Should Invesco S&P 100 Equal Weight ETF (EQWL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for EQWL
CVS Health (CVS) Q3 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Robust sales growth across all three operating segments drove CVS Health's (CVS) third-quarter results.
CVS Health (CVS) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for CVS Health (CVS) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Arhaus (ARHS) Gears Up to Post Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Arhaus' (ARHS) third-quarter 2023 results are likely to have gained from robust demand for products, strength in the showroom and e-commerce channels and normalization of the supply chain.
Wall Street Analysts Look Bullish on CVS Health (CVS): Should You Buy?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in CVS Health (CVS). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
by Zacks Equity Research
Sector ETF report for RSPH
CVS Health Corporation (CVS) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
CVS Health (CVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Overstock (OSTK) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Overstock's (OSTK) third-quarter 2023 results are likely to reflect strength in the Bed Bath & Beyond brand. However, weakening consumer engagement in the housing market is likely to have been a concern.
What's in Store for STMicroelectronics (STM) in Q3 Earnings?
by Zacks Equity Research
STMicroelectronics' (STM) third-quarter results are likely to reflect product portfolio strength and end-market momentum despite macroeconomic challenges.
CVS Health (CVS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
CVS Health (CVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These 2 Retail and Wholesale Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
What to Note Ahead of Deckers Outdoor's (DECK) Q2 Earnings
by Zacks Equity Research
Deckers Outdoor's (DECK) Q2 results might have been hurt by softness across its brands, rising expenses and macroeconomic headwinds. Its customer-centric product and marketing strategies are likely to have been tailwinds.
CVS Health (CVS) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
In the latest trading session, CVS Health (CVS) closed at $68.97, marking a -0.03% move from the previous day.
CVS Health (CVS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
CVS Health (CVS) Q3 revenues will likely benefit from growth in specialty pharmacy and brand inflation and increased prescription and front store volume.
Is Invesco S&P 100 Equal Weight ETF (EQWL) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for EQWL
CVS Health (CVS) Stock Moves -1.28%: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed at $71.09 in the latest trading session, marking a -1.28% move from the prior day.
Bear of the Day: Walgreens Boots Alliance (WBA)
by Brian Bolan
Competition heated up and Walgreens got the boot.
Is There Enough Value to Buy CVS or Best Buy Stock for a Rebound?
by Shaun Pruitt
When it comes to value investing, Best Buy (BBY) and CVS (CVS) stock should certainly be on investors' radars but is it time to buy?
These 2 Retail and Wholesale Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
CVS Health (CVS) Stock Moves -0.63%: What You Should Know
by Zacks Equity Research
In the latest trading session, CVS Health (CVS) closed at $69.25, marking a -0.63% move from the previous day.
Will CVS Health (CVS) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
CVS Health (CVS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Retain CVS Health (CVS) Stock for Now
by Zacks Equity Research
Investors continue to remain optimistic about CVS Health (CVS) due to the new acquisitions and the strong execution of the pharmacy business.